Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)
- Registration Number
- NCT05067478
- Lead Sponsor
- Urovant Sciences GmbH
- Brief Summary
This study will evaluate the treatment satisfaction, discontinuation, reasons for discontinuation, quality of life, healthcare resource utilization, and safety with Vibegron for the treatment of OAB in the context of real-world clinical practice.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 403
- Diagnosis of overactive bladder (OAB) with or without urgency urinary incontinence
- Symptoms of OAB for at least 3 months prior to the Baseline Visit
- Willing and able to complete electronic patient-reported outcomes questionnaires monthly for a minimum of 1 year
- Previous exposure to anticholinergics or mirabegron monotherapy and/or mirabegron plus solifenacin combination therapy prior to initiation of vibegron
- Any contraindication to the use of vibegron per the United States label
- History of OAB treatment with botulinum toxin A; sacral neuromodulation; percutaneous tibial nerve stimulation; external beam radiation therapy; urinary stents within the last 6 months; pelvic or lower urinary tract surgery within the last 6 months; and urethral catheterizations within the last 3 months prior to the Baseline Visit
- History of mixed incontinence where stress incontinence is the predominant form (as determined by the investigator)
- Participants at risk of urinary retention (as determined by the investigator)
- Neurologic conditions associated with OAB symptoms, e.g., multiple sclerosis
- Pregnant or breastfeeding or plans to do so during the study
- Use of vibegron prior to the Baseline Visit either prescribed or in a previous vibegron clinical trial where the participant was on vibegron
- Anyone who, at the discretion of the investigator, is not suitable for treatment with a beta 3 agonist for OAB for any reason
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Cohort B Vibegron Vibegron Participants with previous mirabegron monotherapy or mirabegron plus solifenacin or combination therapy experience will receive vibegron as per the U.S. label. Cohort A Vibegron Vibegron Participants with previous anticholinergic therapy experience will receive vibegron as per the United States (U.S.) label.
- Primary Outcome Measures
Name Time Method Mean Satisfaction Domain Score as Assessed by the Overactive Bladder Satisfaction with Treatment Questionnaire (OAB-SAT-q) Month 3 The OAB-SAT-q is an 11-item questionnaire designed to assess participant's satisfaction with overactive bladder treatment in the clinical setting. It includes 3 subscales (satisfaction, side effects, endorsement) and 2 single-item assessments (convenience, preference), with a 4-week recall period. The OAB-SAT-q is scored by domains ranging from 0-100. Scores for the Convenience item range from 0-100. The Preference item is calculated as a percentage. Higher scores indicate higher levels of treatment satisfaction, endorsement, and convenience.
Mean Satisfaction Domain Score as Assessed by the OAB-SAT-q Month 12 The OAB-SAT-q is an 11-item questionnaire designed to assess participant's satisfaction with overactive bladder treatment in the clinical setting. It includes 3 subscales (satisfaction, side effects, endorsement) and 2 single-item assessments (convenience, preference), with a 4-week recall period. The OAB-SAT-q is scored by domains ranging from 0-100. Scores for the Convenience item range from 0-100. The Preference item is calculated as a percentage. Higher scores indicate higher levels of treatment satisfaction, endorsement, and convenience.
- Secondary Outcome Measures
Name Time Method Percentage of Positive Responders to Individual Treatment Satisfaction Questions 1-3 and 11 as Assessed by the OAB-SAT-q Month 3, Month 6 and Month 12 Number of Participants Discontinuing Vibegron Treatment for the Indicated Reasons Month 3, Month 6 and Month 12 Mean Scores on the Side Effects, Endorsement, Convenience, and Preference Domains as Assessed by the OAB-SAT-q Month 3, Month 6 and Month 12 Number of Participants with Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) Up to Month 12 Percentage of Participants Discontinuing Vibegron Treatment for the Indicated Reasons Month 3, Month 6 and Month 12 Mean Duration of Vibegron Treatment Month 3, Month 6 and Month 12
Trial Locations
- Locations (63)
Urology Centers of Alabama
🇺🇸Homewood, Alabama, United States
43rd Medical Associates
🇺🇸Phoenix, Arizona, United States
Fiel Family and Sports Medicine, PC
🇺🇸Tempe, Arizona, United States
Arkansas Urology Associates, PA
🇺🇸Little Rock, Arkansas, United States
Golden Gate Urology
🇺🇸Berkley, California, United States
Urology Associates of Norwalk
🇺🇸Norwalk, Connecticut, United States
Urological Research Network
🇺🇸Hialeah, Florida, United States
University of Florida Health Jacksonville Facility Clinic
🇺🇸Jacksonville, Florida, United States
South Florida Research Phase I-IV, Inc.
🇺🇸Miami Springs, Florida, United States
University of Miami Miller School of Medicine
🇺🇸Miami, Florida, United States
Scroll for more (53 remaining)Urology Centers of Alabama🇺🇸Homewood, Alabama, United States